Abivax Shares Surge as Obefazimod Delivers Strong Phase 3 Results in Difficult-to-Treat Ulcerative Colitis
Abivax advances toward Q4 2026 NDA filing with encouraging remission and safety results.
XY Feed↓
/ What's going on?
Filter:
FDA Clears Gain Therapeutics’ GT-02287 for Phase 2 Parkinson’s Trials
Phase 2 trials in early Parkinson’s to start Q3 2026 in U.S. & Europe after strong Phase 1 biomarker and safety data.
Edwards’ Ecliptis Wins FDA Clearance, Challenges AtriCure in Surgical LAA Market
Edwards got FDA OK for heart clip; it enters a market led by AtriCure, adding competition but not changing the outlook much.
QuidelOrtho Eyes $1.5B Sale of COVID-Era Rapid Testing Business
The unit, once a pandemic star, attracts strong private equity interest.
Palisade Bio Stock Surges on Positive FDA Clearance for Next-Gen IBD Therapy
The FDA has cleared Palisade Bio’s investigational new drug application for PALI-2108. The company will now start its Phase 2 ASCENTRA-UC trial in H2 2026.
BofA Downgrades Biohaven to Underperform, Cuts Price Target to $11 on Kv7 Risks
Analyst highlights competition risk in Kv7 epilepsy program and cuts peak sales forecast.
Evommune’s EVO756 Fails Phase 2b Trial in Chronic Spontaneous Urticaria, Development Discontinued
Evommune reported EVO756 failed to meet its primary endpoint in the Phase 2b CSU trial. The company is discontinuing development in urticaria but advancing the drug in atopic dermatitis with data expected in Q3 2026.
Nomlabofusp Shows 100% Frataxin Response in Friedreich’s Ataxia — But Anaphylaxis Risk Weighs on Shares
Positive long-term data for Larimar’s nomlabofusp in Friedreich’s ataxia: 100% frataxin response and walking recovery signals. FDA accelerated pathway opens, but safety issues weigh on stock.
Zymeworks to Acquire Theravance Biopharma for $17 Per Share in Cash Plus CVR
The deal adds YUPELRI to Zymeworks’ portfolio.
Lantheus Gets FDA CRL for LNTH-2501; No Safety or Efficacy Concerns Raised
The delay is due to manufacturing issues at a third-party facility, with no safety or clinical data concerns.
Ardelyx Suffers Legal Setback as Appeals Court Confirms XPHOZAH in Medicare Bundle
Ardelyx shares fell after losing a court case on Xphozah Medicare coverage, moving drug into bundled payments, hurting revenue outlook.
Moderna Shares Surge as Oncology Pipeline Ignites Investor Optimism
Piper Sandler raised its price target on Moderna from $69 to $77, maintaining an Overweight rating. Strong momentum in the oncology pipeline is fueling the rally.
Capricor Shares Fall as FDA Schedules Advisory Committee for Deramiocel
Capricor Therapeutics stock fell after the Food and Drug Administration set a July 29 review of its DMD therapy; a decision is due Aug. 22.
JPMorgan Upgrades Replimune to Overweight as FDA Sets Late-July Advisory Committee for RP1
Replimune receives FDA priority review for RP1 in advanced melanoma with August 2, 2026 PDUFA date.
Omeros Shares Plunge After CHMP Rejects Narsoplimab for TA-TMA
Omeros shares fell sharply after the CHMP gave a negative opinion on its drug narsoplimab for transplant-associated thrombotic microangiopathy. Company plans re-examination.
After Re-examination, CHMP Recommends Approval of DAYBU for Rett Syndrome in the EU
Acadia’s DAYBU gets EU positive opinion for Rett syndrome; could become first approved treatment for symptoms in Europe.
Rademikibart Breakthrough Potential: Piper Sandler Sees First-in-Class Opportunity at CNTB
Rademikibart offers first-mover potential in acute asthma & COPD with major Phase 2 data coming in September 2026.
Jefferies Upgrades Tango Therapeutics to Buy, Lifts Price Target to $60 on Promising Pancreatic Cancer Data
Jefferies turned bullish on Tango Therapeutics as early cancer data and big market potential lifted its price target.
Tempus AI Shares Rise on New Angiosarcoma Research Collaboration
Tempus AI announces research collaboration with Angiosarcoma Awareness, analyzing ~600 patient records with paired DNA/RNA data to accelerate rare cancer insights.
ARS Pharmaceuticals Shares Plunge as Neffy Misses July Insurance Wins
Despite the setback, Florida Medicaid coverage begins July 1, the company cut 2026 expenses to $248M, and it remains on track for cash-flow breakeven in 2027.
Merck KGaA Bolsters Life Sciences Portfolio with $11.3B Bio-Techne Acquisition
Acquisition of a medical tools maker will be the German group’s biggest in over a decade.
Passage Bio to Merge with Remix Therapeutics in All-Stock Deal, Raises $100 Million
The combined company will operate as Remix Therapeutics and raised $100M to advance its RNA-targeted pipeline into 2028.
Raymond James Highlights Viking’s New Amylin-Based Weight Loss Drug VK3019 Entering Clinic
Viking Therapeutics advances its obesity portfolio with the start of a Phase 1 trial for VK3019, a novel dual amylin and calcitonin receptor agonist. Analyst sees major potential.
Cantor Fitzgerald Initiates Overweight Coverage on Silence Therapeutics, Calls Stock “Materially Undervalued”
The firm initiated Overweight coverage citing strong divesiran Phase 2 potential and 160%+ upside.
CEO Moshe Mizrahy’s Group Offers to Take InMode Private at $16.20 Per Share
Board forms special committee to evaluate the offer.
Absci Rockets on Positive ABS-201 Data and $100M Financing Backed by Eli Lilly
Eli Lilly participates in Absci’s $100M equity offering to fund ABS-201, a novel prolactin receptor antibody showing strong safety in Phase 1 for pattern hair loss and endometriosis.
Sangamo Therapeutics Files for Chapter 11 Bankruptcy, Strikes Asset Deals with Eli Lilly and Astellas
The deals cover key gene therapy platforms and the Fabry disease program in a court-supervised auction.
Zcash Miner Fortitude to List on Nasdaq Through Merger with HeartSciences
The combined company will list on Nasdaq under the ticker TUDE in H2 2026.
Serapha Bio to Go Public via Merger with Boundless Bio, Raising $230 Million
Boundless Bio and Serapha Bio announce a merger and $230 million private placement. The combined company will advance SERP-01, a base editing therapy for Alpha-1 Antitrypsin Deficiency (AATD).
MacroGenics to Receive $24.5 Million Milestone Payment from Sanofi Following FDA Approval of TZIELD for Stage 3 Type 1 Diabetes
MacroGenics receives $24.5 million from Sanofi after FDA expands TZIELD approval to children aged 8-17 with newly diagnosed stage 3 Type 1 diabetes.
Profit-Taking Hits Moderna Stock After mRNA-1010 Wins Unanimous FDA Panel Backing
Decision due Aug 5, 2026. Potential 2026–27 launch.
Praxis Precision Medicines Wins FDA Breakthrough Status for Elsunersen in Rare Epilepsy
Phase 2 data showed 77% seizure reduction and sustained benefits up to 1 year.
EB613 Set to Become First Once-Daily Oral Tablet for Osteoporosis as Entera Bio Advances to Phase 3
Entera Bio receives positive FDA feedback on its pivotal Phase 3 trial design for EB613, the potential first once-daily oral tablet to stimulate bone formation in postmenopausal women with osteoporosis.
No Efficacy or Safety Issues: Achieve Life Sciences Gets FDA CRL for Cytisinicline
Achieve Life Sciences received an FDA Complete Response Letter for its cytisinicline NDA due to manufacturing issues at a former facility. No efficacy or safety deficiencies were identified.
Breakthrough LSD-Derived Drug DT120 Shows Dramatic Antidepressant Effect in Phase 3 Trial
Definium’s DT120 pill showed strong fast and lasting depression relief in Phase 3, with good safety and big symptom cuts.
FDA Aligns with REGENXBIO on Accelerated Approval Pathway for NAVSUNLI Gene Therapy in Hunter Syndrome
FDA reverses course and agrees to review existing data for NAVSUNLI gene therapy in Hunter syndrome.
Leerink Initiates Outperform on Altimmune: Pemvidutide Poised for MASH Success with $10 Target
Pemvidutide demonstrates strong MASH resolution, weight loss, and cardiometabolic benefits, with significant analyst upside.
AbbVie Bolsters Immunology Pipeline with $10.9 Billion Apogee Acquisition
The acquisition would add a longer-acting alternative to Dupixent for inflammatory diseases.
MoonLake’s Sonelokimab Achieves High Response Rates in HS After 12 Months
Sonelokimab shows strong 1-year results in HS, with many patients seeing clear skin, less pain, and better quality of life, with good safety.
Butterfly Network Soars as Midjourney Enters Medical Imaging with Revolutionary Full-Body Ultrasound Scanner
AI-powered 60-second scans could transform preventive healthcare.
Pfizer Announces Departure of CFO Dave Denton, Names Interim Successor
Cecile Guegan named Interim CFO as the company reaffirms its 2026 guidance.
Novocure Stock Plunges After Phase 3 TRIDENT Study Fails to Meet Primary Goal
Novocure’s Phase 3 TRIDENT trial failed to show survival benefit from earlier TTFields initiation in newly diagnosed glioblastoma.
Wall Street Initiates Coverage on IMMX, PRAX & RNA with Buy Ratings – Morgan Stanley Downgrades ENGN
BofA initiates coverage on IMMX with a Buy rating and $27 price target. RBC starts PRAX with Outperform ($449 PT), while Cantor begins coverage on RNA. Morgan Stanley downgrades ENGN to Underweight.
Biogen Acquires RayThera for Up to $1 Billion to Expand Immunology Pipeline
The deal adds multiple early-stage small-molecule immunology assets to Biogen’s pipeline, with the lead candidate entering Phase 1 in Q3 2026.
FDA Clears Path for AXPAXLI: Ocular Therapeutix Targets Late 2026 NDA Submission
Ocular Therapeutix has reached alignment with the FDA to submit the AXPAXLI NDA for wet AMD in Q4 2026, based on SOL-1 data and interim SOL-R safety results. Topline SOL-R data now expected in Q1 2028.
Jazz Pharmaceuticals Strikes Major Collaboration with AbCellera for Next-Generation Multispecific Antibodies
Jazz Pharmaceuticals and AbCellera enter a collaboration worth up to $876 million to develop next-generation T-cell engaging multispecific antibodies for GI cancers and solid tumors.
Elicio Reports Multiple Complete Responses in Metastatic Pancreatic Cancer After ELI-002 7P and Checkpoint Inhibitor Therapy
Elicio reports three complete responses in metastatic mKRAS pancreatic cancer after ELI-002 7P treatment followed by nivolumab. Company plans Phase 1 combination study.
FDA Signals Accelerated Approval Path for uniQure’s Huntington’s Gene Therapy AMT-130
uniQure receives positive FDA feedback for accelerated approval of its one-time gene therapy AMT-130 for Huntington’s disease. BLA submission planned for Q3 2026.
Edwards Lifesciences Gets Big Boost as CMS Expands TAVR Coverage to Asymptomatic Patients
TAVR is Edwards’ main business. New CMS rules could boost sales and help it take market share from Medtronic and Boston Scientific.
Moderna Strengthens Commercial Leadership Ahead of Flu and Norovirus Vaccine Launches
Moderna names Ester Banque, ex-Zoetis/Novartis, as Chief Commercial Officer as it prepares for potential 2027 launches of combined flu-COVID, standalone flu, and norovirus vaccines. FDA advisory on mFLUSIVA this week.
Eli Lilly Acquires 4E Therapeutics to Strengthen Non-Opioid Pain Pipeline
Eli Lilly has acquired 4E Therapeutics, a neuroscience biotech developing non-opioid treatments for chronic pain. This marks Lilly’s 11th deal of 2026 and strengthens its non-opioid pain pipeline.
PepGen Shares Trading Below Cash as Craig-Hallum Starts Coverage with Buy Rating
PepGen has Buy ratings; DM1 drug data mixed, big 2026 results could drive huge upside from very low stock price.
Altaris to Acquire Simulations Plus for $375 Million in All-Cash Deal
Shareholders get $18.50 per share. The company is expected to combine with Chemical Computing Group after closing. Deal expected to close in Q4 2026.
Edgewise Shares Fall Despite Encouraging Phase 2 Results in Obstructive and Nonobstructive HCM
Edgewise shared encouraging Phase 2 CIRRUS-HCM results for EDG-7500, showing strong improvements in symptoms, biomarkers, and diastolic function across both types of HCM. Larger Phase 3 trials will be required before any approval.
JPMorgan Sees 127% Upside in Camp4 Therapeutics as It Upgrades to Overweight on CMP-002 Potential
JPMorgan upgrades Camp4 to Overweight, sees strong upside from CMP-002, with trials planned in 2026 and promising early results.
Adaptive Biotechnologies Plans to Split Its MRD and Immune Medicine Units
The company expects to decide the best path by year-end 2026.
H.C. Wainwright Says CNTX Stock Drop Is 'Overdone' After CTIM-76 Ovarian Cancer Data
Context Therapeutics reported positive Phase 1 data for CTIM-76 in heavily pretreated platinum-resistant ovarian cancer, showing a 29% response rate and good safety, but the stock fell due to small trial size.
CMS Plans Permanent Medicare Drug Price Negotiations Starting 2029 – What It Means for Big Pharma
Medicare plans drug price cuts from 2029, hitting pharma stocks, but long-term impact may be limited by legal and market protections.
enGene Lays Off 50% of Staff and Stops Patient Enrollment to Save Cash
enGene is reducing its workforce by ~50% and has stopped patient enrollment in three additional LEGEND trial cohorts to preserve cash while focusing on its pivotal data and planned BLA filing.
Analysts Reiterate Buy Ratings on Intellia as lonvo-z Shows Deeper Benefits in HAELO Trial
Intellia’s one-time gene therapy cut HAE attacks ~90%, boosting hopes for a lasting treatment; FDA review underway, launch possible in 2027.
Oppenheimer Sees 440% Upside in Acrivon Therapeutics as Key ACR-368 Data Approaches
Cancer drug ACR-368 shows strong early results in endometrial trials biomarker-driven response.
Neumora Halts Navacaprant Development After Phase 3 Depression Trials Fail
Neumora stopped navacaprant after failed depression trials, cut 35% jobs, shares fell, but keeps advancing 3 other drugs.
Elicio Stock Falls After Phase 2 Pancreatic Cancer Trial Misses Primary Endpoint
Elicio stock plunged after Phase 2 failed main goal, but showed cancer benefit in selected patients.
Twist Bioscience Stock Surges Toward $1 Billion Goal as Canaccord Joins Bullish Chorus
Canaccord is bullish on Twist Bioscience, citing AI-driven DNA tech growth, strong revenue gains, and upside to $90 target.
Traws Pharma Puts Phase 2 Influenza Trial on Hold After UK Regulator Feedback
Traws Pharma shares fell after delaying its Phase 2 human influenza challenge study due to negative feedback from the UK’s MHRA. The company is now advancing backup flu antiviral candidates.
Raymond James Bullish on Dianthus as Claseprubart Outperforms Expectations in Early CAPTIVATE Results
Raymond James reiterated its Strong Buy rating and $125 price target on Dianthus after the company reported strong early data from the Phase 3 CAPTIVATE study of claseprubart in CIDP.
Medline Tracy Warehouse Destroyed in Fire; Short-Term Disruption Expected
The company is activating contingency plans, which may cause short-term supply disruptions. Analysts expect limited long-term impact.
MBX Biosciences’ Canvuparatide Shows Solid One-Year Data but Misses Market Expectations
MBX reports 57% response at 1 year for canvuparatide in hypoparathyroidism with stable safety, but shares fell on modest results.
Avalo Therapeutics Stock: BofA Sees 156% Upside with New Buy Rating
Strong analyst support for abdakibart in hidradenitis suppurativa as Avalo advances to Phase 3.
Adial Pharmaceuticals Acquires Azora and Raises Up to $64 Million for New Ulcerative Colitis Drug
Adial Pharmaceuticals acquires Azora Therapeutics and raises up to $64 million to advance AT177, a novel colon-targeted therapy for ulcerative colitis. Phase 1 studies planned for mid-2027.
5 Hot Biotech Stocks With Fresh Buy Ratings
Analysts initiate coverage with Buy ratings on Sensei (SNSE), Septerna (SEPN), Kazia (KZIA), NervGen (NGEN), and Sutro (STRO).
Enliven Therapeutics’ ELVN-001 Delivers Strong Results in Phase 1 CML Study, Aligns with FDA on Phase 3 Design
Early results show performance that is comparable to a widely used Novartis blockbuster and a Merck-owned experimental treatment.
Casgevy Outlook: Morgan Stanley’s Take on CRISPR Therapeutics
Morgan Stanley upgraded CRISPR Therapeutics to Equal Weight, $60 target (~21% upside), sees Casgevy growth but mixed valuation views.
Humacyte Shares Slide on Stock Sale Despite Positive Dialysis Trial Data
Humacyte shares dropped following a $50M stock offering announcement. The move comes even as the company reported strong interim Phase 3 data for its ATEV in female dialysis access patients.
Chardan Slaps “Buy” Rating on CAMP4 Therapeutics – $6.50 Price Target Signals 60%+ Upside
Its new gene-boosting drug shows promise for rare brain disorders with no treatments yet.
B. Riley Sees Multi-Billion Dollar Potential in Elicio’s mKRAS Vaccine
B. Riley sees Elicio as a strong Buy; mKRAS cancer vaccine data in June could be a major stock catalyst.
Clover Health Triumphs in Court – Massive 4.5-Star Medicare Rating Upgrade
Clover Health got its Medicare rating raised to 4.5 stars, boosting future government bonus payments from 2027.
Barclays Predicts Oscar Health Will Benefit Most from ACA Boom
Barclays raised Oscar Health rating, sees higher price target as ACA growth and pricing gains boost future profits.
Sanofi’s Phase 3 CIDP Failure Hits Riliprubart and Raises Doubts for Dianthus’ Claseprubart
Sanofi discontinues its Phase 3 MOBILIZE study of riliprubart in refractory CIDP after failing to show efficacy. The setback raises major doubts for Dianthus’ claseprubart (C1s inhibitor).
Cellectis Receives FDA RMAT Status for lasme-cel – First Allogeneic CAR-T in Pivotal Trial for r/r B-ALL
Cellectis got FDA RMAT for lasme-cel, an off-the-shelf CAR-T therapy for hard-to-treat leukemia that may speed up patient access.
Perrigo CEO Resigns Over Personal Conduct – Interim Leader Named
Perrigo CEO resigned over conduct issues; interim CEO Albert Manzone appointed; company keeps 2026 sales and earnings targets unchanged.
FDA Greenlights Alterity’s Phase 3 Plan for ATH434 in Multiple System Atrophy
Alterity’s drug ATH434 slowed MSA progression in trials, and FDA-approved Phase 3 plans bring it closer to becoming the first real treatment.
Sephience Sales Momentum Prompts Citi to Upgrade PTC Therapeutics to Buy
Citi turns bullish on PTCT, citing strong Sephience sales in PKU and potential $1B+ peak, raising target to $108.
Novanta Buys Riverpoint Medical for Up to $1.45B to Boost Minimally Invasive Surgery Portfolio
Novanta to buy Riverpoint Medical for up to $1.45B, doubling its recurring medical consumables revenue and expanding into minimally invasive surgical devices. Deal expected to close Q3 2026.
Oppenheimer Launches Coverage on DTIL with Outperform Rating – 100%+ Upside Ahead?
Oppenheimer rates DTIL “Outperform” ($20). ARCUS gene editing shows promise in DMD & Hep B with big upside potential.
GSK Buys Nuvalent for $10.6 Billion in Massive Cancer Drug Bet
The deal gives GSK two potential best-in-class lung cancer drugs and accelerates its oncology growth.
Biggest Nursing Home Company Accused of Cutting Corners on Patient Care
Hunterbrook report accuses Ensign Group of understaffing, gaming metrics, and patient neglect.
FDA Accepts Alvotech’s AVT16 – A New Interchangeable Biosimilar to Entyvio
Alvotech’s AVT16 biosimilar to Entyvio is under FDA review, aiming for cheaper, interchangeable treatment for gut diseases.
Johnson & Johnson Acquires Firefly Bio for $1B to Unlock New Cancer Treatments
The deal brings Firefly’s Firelink platform that precisely targets hard-to-treat KRAS-driven tumors while sparing healthy tissue.
Nurix and Roche Team Up in Massive $2.3B Partnership for Next-Gen Blood Cancer Treatment
Nurix Therapeutics gets $700M upfront in a potential $2.3B partnership with Roche to co-develop bexobrutideg, a next-gen oral BTK degrader for CLL, MS, and immunology.
Tango Therapeutics Achieves 92% Response Rate in Hard-to-Treat Pancreatic Cancer
Tango drug combo shows 92% response in advanced pancreatic cancer, with strong early results and good safety in trials.
Incyte Buys Vega Therapeutics for Up to $2 Billion to Bring New Once-a-Month Shot for Bleeding Disorder
Incyte is buying Vega Therapeutics to add VGA039 — a new once-monthly under-the-skin injection for von Willebrand disease (VWD).
Cullinan’s CLN-978 Shows Deep B-Cell Depletion and Remissions in Lupus and RA
Cullinan Therapeutics’ CLN-978 T-cell engager showed deep B-cell depletion and clinical remissions in hard-to-treat lupus and rheumatoid arthritis patients after a single dose at EULAR 2026.
Eli Lilly Stock Surges as Retatrutide Delivers 28% Weight Loss and Major Relief for Sleep Apnea & Knee Pain
Lilly stock jumps as new obesity drug helps people lose ~30% body weight and improve health, showing strong promise for future treatment.
FDA Gives Green Light to CardiAMP Heart Cell Therapy for Heart Failure
FDA confirms BioCardia’s CardiAMP Heart Failure II trial may support Premarket Approval for ischemic heart failure.
Roth Capital Initiates Coverage on COYA With Buy Rating and Huge ALS Potential
COYA gets Buy rating; ALS drug COYA 302 shows early promise, could double stock if trials succeed, high risk biotech.
Shattuck Labs Stock Gets Bullish Citi Upgrade Before SL-325 Phase 1 Results
Citi upgrades STTK to Buy with $7 price target and 30-day upside watch ahead of SL-325 Phase 1 data in Q2 2026.
Biogen’s Salanersen Wins FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Biogen’s new SMA drug Salanersen shows strong early results, helping kids move better. FDA fast-tracks it with Breakthrough status.
Liquidia Gets Bullish Signal from Hikma vs Amarin Ruling
Raymond James reiterates Strong Buy rating and $68 target on Liquidia after the Supreme Court’s positive Hikma v. Amarin decision.
Enobosarm Grabs Novo Nordisk’s Attention: Veru’s Big Obesity Breakthrough
Veru partnered with Novo Nordisk to test enobosarm + Wegovy for fat loss while keeping muscle; stock surged.